The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft ModelsAlwin G. Schuller(AstraZeneca (South Korea)), Celina M. D’Cruz(AstraZeneca (United States))Clinical Cancer ResearchMarch 16, 201510.1158/1078-0432.ccr-14-2685Cited by 80SaveCiteExport RISWatch citationsRelated PapersResistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers|Oncotarget|2014|57